Evaluation of CCL5-403 G>A and CCR5 Δ32 gene polymorphisms in patients with breast cancer

BACKGROUND: Recent evidence has demonstrated the implication of CC chemokine ligand 5 (CCL5) and CC chemokine receptor 5 (CCR5) in breast tumor initiation and progression. OBJECTIVE: The purpose of this study was to investigate whether single nucleotide polymorphisms of CCL5 -403 G>A (rs2107538) and CCR5 Delta 32 genes are associated with the breast cancer (BC) risk. METHODS: A total of 439 subjects including on 236 BC patients and 203 healthy controls from the same area were recruited. The CCL5 -403 G>A and CCR5 Delta 32 polymorphisms were genotyped by allele-specific polymerase chain reaction (AS-PCR) and PCR, respectively. RESULTS: Our data demonstrated that the CCL5 -403 GA and GA+AA genotypes, with a higher frequency in the BC patients compared to the control group, were associated with an increased risk of BC in the codominant (GG vs. GA OR = 1.75, 95% CI = 1.07-2.86, P = 0.025) and dominant models (GG vs. GA+AA: OR = 1.84, 95% CI = 1.15-2.93, P = 0.014), respectively. Additionally, the A allele of CCL5 -403 G>A variation was found more prevalent in the BC patients than in controls (14% vs. 8%) and was a risk factor for BC (G vs. A: OR = 1.87, 95% CI = 1.21-2.89, P = 0.004). CONCLUSIONS: Our findings highlighted that the CCL5 -403 G>A polymorphism is a risk factor for BC in our population. Our findings suggest that the CCL5 -403 GA and GA+AA genotypes and the A allele were associated with an elevated risk of BC which may function as risk factor for breast carcinoma.